489 related articles for article (PubMed ID: 27889880)
1. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Narita T; Koie T; Ookubo T; Mitsuzuka K; Narita S; Yamamoto H; Inoue T; Hatakeyama S; Kawamura S; Tochigi T; Habuchi T; Arai Y; Ohyama C
Med Oncol; 2017 Jan; 34(1):1. PubMed ID: 27889880
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Matsumoto T; Hatakeyama S; Ookubo T; Mitsuzuka K; Narita S; Inoue T; Yamashita S; Narita T; Koie T; Kawamura S; Tochigi T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C
Med Oncol; 2017 Oct; 34(12):190. PubMed ID: 29090390
[TBL] [Abstract][Full Text] [Related]
4. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.
Fujita N; Koie T; Ohyama C; Tanaka Y; Soma O; Matsumoto T; Yamamoto H; Imai A; Tobisawa Y; Yoneyama T; Hatakeyama S; Hashimoto Y
Int J Clin Oncol; 2017 Dec; 22(6):1087-1093. PubMed ID: 28681153
[TBL] [Abstract][Full Text] [Related]
5. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
[TBL] [Abstract][Full Text] [Related]
7. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
[TBL] [Abstract][Full Text] [Related]
8. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
9. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
Fossati N; Willemse PM; Van den Broeck T; van den Bergh RCN; Yuan CY; Briers E; Bellmunt J; Bolla M; Cornford P; De Santis M; MacPepple E; Henry AM; Mason MD; Matveev VB; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Lam TB; Mottet N; Joniau S
Eur Urol; 2017 Jul; 72(1):84-109. PubMed ID: 28126351
[TBL] [Abstract][Full Text] [Related]
10. Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial.
Touijer KA; Sjoberg DD; Benfante N; Laudone VP; Ehdaie B; Eastham JA; Scardino PT; Vickers A
Eur Urol Oncol; 2021 Aug; 4(4):532-539. PubMed ID: 33865797
[TBL] [Abstract][Full Text] [Related]
11. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.
Heidenreich A; Ohlmann CH; Polyakov S
Eur Urol; 2007 Jul; 52(1):29-37. PubMed ID: 17448592
[TBL] [Abstract][Full Text] [Related]
12. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
Lestingi JFP; Guglielmetti GB; Trinh QD; Coelho RF; Pontes J; Bastos DA; Cordeiro MD; Sarkis AS; Faraj SF; Mitre AI; Srougi M; Nahas WC
Eur Urol; 2021 May; 79(5):595-604. PubMed ID: 33293077
[TBL] [Abstract][Full Text] [Related]
13. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
[TBL] [Abstract][Full Text] [Related]
14. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
[TBL] [Abstract][Full Text] [Related]
15. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Kamimura N
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):397-401. PubMed ID: 22890389
[TBL] [Abstract][Full Text] [Related]
17. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
[TBL] [Abstract][Full Text] [Related]
18. Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.
Iwamura H; Hatakeyama S; Narita T; Ozaki Y; Konishi S; Horiguchi H; Kodama H; Kojima Y; Fujita N; Okamoto T; Tobisawa Y; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Sci Rep; 2022 Jun; 12(1):9675. PubMed ID: 35690635
[TBL] [Abstract][Full Text] [Related]
19. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.
Yaxley JW; Dagher J; Delahunt B; Egevad L; Srigley J; Samaratunga H
World J Urol; 2018 Jan; 36(1):15-20. PubMed ID: 29116393
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]